Researcher: Thalidomide Does Not Slow Malignant Pleural MesotheliomaResearch & Clinical Trials
Asbestos.com is the nation’s most trusted mesothelioma resource
The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.
Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.
More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.
About The Mesothelioma Center at Asbestos.com
- Assisting mesothelioma patients and their loved ones since 2006.
- Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
- A+ rating from the Better Business Bureau.
- 5-star reviewed mesothelioma and support organization.
"My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family."LashawnMesothelioma patient’s daughter
How to Cite Asbestos.com’s Article
Franz, F. (2020, October 16). Researcher: Thalidomide Does Not Slow Malignant Pleural Mesothelioma. Asbestos.com. Retrieved January 26, 2023, from https://www.asbestos.com/news/2011/11/17/researcher-thalidomide-does-not-slow-malignant-pleural-mesothelioma/
Franz, Faith. "Researcher: Thalidomide Does Not Slow Malignant Pleural Mesothelioma." Asbestos.com, 16 Oct 2020, https://www.asbestos.com/news/2011/11/17/researcher-thalidomide-does-not-slow-malignant-pleural-mesothelioma/.
Franz, Faith. "Researcher: Thalidomide Does Not Slow Malignant Pleural Mesothelioma." Asbestos.com. Last modified October 16, 2020. https://www.asbestos.com/news/2011/11/17/researcher-thalidomide-does-not-slow-malignant-pleural-mesothelioma/.
Noted mesothelioma researcher Paul Baas, M.D., announced Thursday that using thalidomide as part of a treatment regimen for malignant pleural mesothelioma does not slow the progression of the cancer.
Baas, lead researcher for the Netherlands Cancer Institute, briefed other cancer scientists on the news Thursday from Perth, Australia, on the final day of the Clinical Oncology Society of Australia’s 2011 Annual Scientific Meeting. COSA released details of Baas’s briefing. The study was performed jointly by scientists from The Netherlands and Australia.
“Thalidomide has been shown to be effective in the treatment of hematological cancers such as leukemia, so it was logical to test the potential of the drug in solid tumors,” Baas said.
But thalidomide, an anti-vascular agent, was not effective in the study. Over a 12-month period, researchers looked at 207 patients that did not display signs of cancer progression while being treated with a another drug regime. Patients, who had a median age of 64, had CT scans of their thorax and physical exams at least every eight weeks, Baas told the group.
After a year, however, researchers could show no slowing of the cancer growth. Pleural mesothelioma accounts for about 75 percent of all cases. About 38 percent of patients survive one year; about 11 percent survive two years, according to the National Cancer Institute.
“This means we must reconsider our strategies and assess other options such as surgery, radiation therapy and other targeted agents,” Baas said.
Mesothelioma is a highly rare cancer. It claims between 2,500 and 3,000 lives a year in the United States, and about 3,000 cases are diagnosed each year. The cancer is caused by exposure to asbestos, and people are typically exposed at work.
There is no known cure for mesothelioma, and researchers are eager to find signs of hope in a multitude of clinical trials.
Baas was scheduled to brief fellow researchers on another Phase III trial, that of the use of Vorinostat in patients with advanced malignant pleural mesothelioma (MPM). The random, double-blind trial studied people who failed prior pemetrexed and either cisplatin or carboplatin therapy. Details of the study’s results were not available.